Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novabay Pharmaceuticals (NY: NBY )

0.7100 -0.0200 (-2.74%)
Official Closing Price Updated: 4:10 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 320,485
Open 0.7000
Bid (Size) 0.6600 (1)
Ask (Size) 0.7000 (2)
Prev. Close 0.7300
Today's Range 0.6802 - 0.7293
52wk Range 0.3611 - 17.74
Shares Outstanding 30,098,150
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With NovaBay Pharmaceuticals Shares Friday?
NovaBay shares are trading higher after the company announced it reached a definitive agreement to sell its Avenova assets for $9.5 million to Physician Recommended Nutraceuticals. 
Via Benzinga
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire

Performance

YTD
-89.58%
-89.58%
1 Month
+40.01%
+40.01%
3 Month
-70.90%
-70.90%
6 Month
-80.62%
-80.62%
1 Year
-95.77%
-95.77%

More News

Read More
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NBY Stock Earnings: NovaBay Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
What's Going On With NovaBay Pharmaceuticals (NBY) Stock?
Via Benzinga
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
S&P 500 Gains Over 1%; 3M Shares Jump After Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why NovaBay Pharmaceuticals (NBY) Stock Is Down 60%
Via Benzinga
Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results
Via Benzinga
Exposures Fossil Fuels
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Dow Surges 550 Points; Headline PCE Price Index Falls To 2.5%
Via Benzinga
Topics Stocks
Exposures US Equities
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why Ultra Clean Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Gold Gains 1%; Best Buy Posts Upbeat Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.